Establishment of Acenocoumarol Pharmacogenetic Algorithm Including CYP2C9 and VKORC1 Genotypes in Bulgarian Patients Treated with Coumarin Anticoagulants

1 Schalekamp T, De Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr Pharm Des, 2010; 16(2):187-203. Search in Google Scholar

2 Kovac MK, Rakicevic LB, Radojkovic DP. Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypes. J Thromb Thrombolysis, 2011; 32(3):368-71. Search in Google Scholar

3 Wolkanin-Bartnik J, Pogorzelska H, Szperl M, et al. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm. Pharmacogenet Genomics, 2013;23(11):611-8. Search in Google Scholar

4 Van Schie RM, Wessels JA, le Cessie S, et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J, 2011; 32(15):1909-17. Search in Google Scholar

5 Rathore SS, Agarwal SK, Pande S, et al. Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. PLoS One, 2012; 7(5):e37844. Search in Google Scholar

6 Pop TR, Vesa SC, Trifa AP, et al. An acenocoumarol dose algorithm based on a South-Eastern European population. Eur J Clin Pharmacol, 2013. Search in Google Scholar

7 Markatos CN, Grouzi E, Politou M, et al. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics, 2008;9(11):1631-8. Search in Google Scholar

8 Krishna D, Madhan S, Balachander J, et al. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients. Thromb Res, 2013; 131(4):363-7. Search in Google Scholar

9 Cerezo-Manchado JJ, Rosafalco M, Anton AI, et al. Creating a genotype-based dosing algorithm for acenocoumarol steady dose. Thromb Haemost, 2013;109(1):146-53. Search in Google Scholar

10 Borobia AM, Lubomirov R, Ramirez E, et al. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS One, 2012;7(7):e41360. Search in Google Scholar

11 Tzveova, R., A. Dimitrova-Karamfilova, R. Saraeva, et al., Estimation and validation of acenocoumarol dosing algorithms in Bulgarian patients with cardiovascular diseases. Per Med, 2015;12(3):209-220. Search in Google Scholar

12 Schwarz UI, Stein CM. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Clin Pharmacol Ther, 2006;80(1):7-12. Search in Google Scholar

13 Kurnik, D., R. Loebstein, H. Halkin, et al. 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics, 2009;10(12):1955-65. Search in Google Scholar

14 Buzoianu AD, Militaru FC, Vesa SC, et al. The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population. Blood Cells Mol Dis, 2013;50(3):166-70. Search in Google Scholar

15 Smires FZ, Habbal R, Moreau C, et al. Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients. Pathol Biol (Paris), 2013;61(3):88-92. Search in Google Scholar

16 Smires FZ, Moreau C, Habbal R, et al. Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. J Clin Pharm Ther, 2012;37(5): p. 594-8. Search in Google Scholar

17 Pathare A, Al Khabori M, Alkindi S, et al. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. J Hum Genet, 2012;57(10):665-9. Search in Google Scholar

18 Rusdiana T, Araki T, Nakamura T, et al. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol, 2013;69(3):395-405. Search in Google Scholar

19 Bazan NS, Sabry NA, Rizk A, et al. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients. Int J Clin Pharm, 2012;34(6):837-44. Search in Google Scholar

20 Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 2005;106(7):2329-33. Search in Google Scholar

21 Saraeva RB, Paskaleva IB, Doncheva E, et al. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CY-P3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J Clin Pharm Ther, 2007;32(6):641-9. Search in Google Scholar

22 Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood, 2005;106(1):135-40. Search in Google Scholar

23 Kaur A, Khan F, Agrawal SS, et al. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1-1639G<A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement. Indian J Med Res, 2013;137(1):203-9. Search in Google Scholar

24 Kovac MK, Maslac AR, Rakicevic LB, et al. The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy. Blood Coagul Fibrinolysis, 2010;21(6):558-63. Search in Google Scholar

25 Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CY-P2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther, 2006;80(1):13-22. Search in Google Scholar

26 Saraeva, R. Study of polymorphic variants in genes for xenobiotic metabolizing enzymes and glycoprotein-P: association with Balkan endemic nephropathy and with response to acenocoumarol drug therapy. PhD thesis. 2008. Medical University – Sofia. Search in Google Scholar

27 Jose R, Chandrasekaran A, Sam SS, et al. CYP2C9 and CY-P2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol, 2005;19(1):101-5. Search in Google Scholar

28 Visser LE, van Schaik RH, van Vliet M, et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost, 2004;92(1):61-6. Search in Google Scholar

29 Puehringer H, Loreth RM, Klose G, et al. VKORC1-1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. Eur J Clin Pharmacol, 2010;66(6):591-8. Search in Google Scholar

30 Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet, 2005;14(13):1745-51. Search in Google Scholar

31 Arboix M, Laporte JR, Frati ME, et al. Effect of age and sex on acenocoumarol requirements. Br J Clin Pharmacol, 1984;18(4):475-9. Search in Google Scholar

32 Perez-Andreu V, Roldan V, Anton AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood, 2009;113(20):4977-9. Search in Google Scholar

33 Pavani A, Naushad SM, Mishra RC, et al. Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. Pharmacogenomics, 2012;13(8):869-78. Search in Google Scholar

34 Sconce E, Avery P, Wynne H, et al. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood, 2007;109(6):2419-23. Search in Google Scholar

35 Teichert M, Eijgelsheim M, Rivadeneira F, et al. A genomewide association study of acenocoumarol maintenance dosage. Hum Mol Genet, 2009;18(19):3758-68. Search in Google Scholar

36 Wadelius M, Chen LY, Eriksson N, et al. Association of war-farin dose with genes involved in its action and metabolism. Hum Genet, 2007;121(1):23-34. Search in Google Scholar

37 Wadelius M, Sorlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J, 2004;4(1):40-8. Search in Google Scholar

38 Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther, 2008;84(3):326-31. Search in Google Scholar

39 Tham LS, Goh BC, Nafziger A, et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther, 2006;80(4):346-55. Search in Google Scholar